Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425744 | 0.93 | MEN1 (0.52) | MEN1KMT2AUSP2HSD17B10ALOX15 | |
| SCHEMBL3323198 | 0.89 | MEN1 (0.52) | MEN1KMT2AUSP2HSD17B10ALOX15 | |
| SCHEMBL13801457 | 0.88 | MEN1 (0.46) | MEN1KMT2AUSP2HSD17B10ALOX15 | |
| SCHEMBL13801454 | 0.87 | MEN1 (0.51) | MEN1KMT2AUSP2HSD17B10ALOX15 | |
| SCHEMBL10159372 | 0.86 | MEN1 (0.41) | MEN1KMT2AALOX15SMN1; SMN2MAPT | |
| SCHEMBL422090 | 0.81 | MEN1 (0.51) | MEN1KMT2AUSP2HSD17B10ALOX15 | |
| SCHEMBL12772251 | 0.79 | MEN1 (0.55) | MEN1KMT2AUSP2HSD17B10ALOX15 | |
| SCHEMBL430136 | 0.79 | MEN1 (0.48) | MEN1KMT2AALOX15SMN1; SMN2MAPT | |
| SCHEMBL10195931 | 0.77 | KMT2A (0.52) | MEN1KMT2AUSP2HSD17B10ALOX15 | |
| SCHEMBL425231 | 0.77 | MEN1 (0.51) | MEN1KMT2AUSP2HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | MEN1 293/4885KMT2A 1939/4885USP2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.